AKT1 and prostate cancer: Similarly, in prostate cancer, SB-225002 inhibited AKT phosphorylation, thereby blocking the PI3K signaling pathway, while also suppressing the secretion of bone sialoprotein and osteopontin, ultimately attenuating metastatic progression (Xu et al., 2018).